Короткий опис (реферат):
The aim of the study was to determine the clinical portrait of patients
with stage II hypertension at different levels of transforming growth factor β1 (TGF-
β1) in blood plasma. Echocardiography, Holter electrocardiographic monitoring, stress
tests and/or coronary ventriculography were performed in 120 patients (mean age
57.3±0.9 years) to verify the diagnosis of stage II hypertension and concomitant
chronic coronary heart disease (CCHD) and frequent ventricular extrasystole (VE). We
allocated 4 groups of patients (30 persons in each): Group 1 – stage II hypertension
without concomitant CCHD and frequent VE; Group 2 – stage II hypertension with
concomitant frequent VE; Group 3 – stage II hypertension with concomitant CCHD;
Group 4 – stage II hypertension with concomitant CCHD and frequent VE. Using an
enzyme-linked immunosorbent assay with the “Human TGF-β1 (Transforming Growth
Factor Beta 1) ELISA Kit” (Elabscience Biotechnology Inc., USA), the concentration
of TGF-β1 in blood serum was determined according to the manufacturer’s
instructions. Microsoft Excel (2019) and Statistica 12.0 (Statsoft, USA) were then used
for statistical processing of the obtained results. By the method of variation statistics,
the mean plasma concentration of TGF-β1 in the examined patients (n=120) was
9238.3±97.2 pg/mL. The median value was 222.0 pg/mL, and the interquartile range
(25th and 75th percentiles) was 165.5 and 303.0 pg/mL, respectively. Taking the
median into account, we distinguished groups of patients with a relatively low level
(≤222 pg/mL) and a relatively high level (>222 pg/mL) of TGF-β1. It was determined
that in 50% of the examined patients the plasma TGF-β1 concentration was 165.5–
303.0 pg/mL, in 25% it was below 165.5 pg/mL, and in the remaining 25% it was above
303.0 pg/mL. Moreover, an increase in its concentration was observed from Group 1
to Group 4. Clinical portraits of patients with stage II hypertension and different plasma
TGF-β1 levels were determined using discriminant analysis (“Discriminant analysis”).
The baseline parameter for the analysis was the mediator level expressed in points, where 1 point indicated a relatively low level and 2 points indicated a relatively high
level of the hormone for the studied population of patients with stage II hypertension.
Before performing discriminant analysis, a preliminary “filtering” of clinical and
instrumental indicators (n=76) was carried out using Spearman rank correlation to
determine their associations with the plasma hormone level. Indicators that showed a
statistically significant (p<0.05) rank correlation with the plasma hormone
concentration were included in the subsequent discriminant analysis. It was found that
in patients with stage II hypertension and plasma TGF-β1 ≥222 pg/mL the following
clinical portraits should be expected: 1) the presence of concomitant obesity; 2) the
presence of concomitant obesity and angina pectoris without/with frequent VE. In this
case, for functional class II angina the minimum number of VE episodes per day is
5000, whereas for functional class III it is 2500 VE episodes per day; 3) the presence
of concomitant frequent VE >10,000 VE episodes per day.
